Companies · Biotechnology

Uptake Medical Corp

Tustin · Biotechnology

Diligence memoA one-page analyst read on Uptake Medical Corp — recommendation, valuation, rhythm, risks.
$113.2M
Total raised · real
10
Rounds
0.8×
Latest step-up
Top 10%
Sector rank · raised
Series C
Latest stage · inferred · Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Uptake Medical Corp looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.04× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era.
Dormant
  • Last raise 10.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Uptake Medical Corp is one of 4293 Biotechnology companies tracked from Tustin. By capital raised it ranks among the largest (ahead of 91% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeed · 2008-12-22 Raised $3.1M (real) Modeled valuation $139M (est)Seed2008Seed · 2009-08-31 Raised $3.4M (real) Modeled valuation $149M (est)Seed2009Series B · 2009-08-31 Raised $17M (real) Modeled valuation $670M (est)Series B2009Series A · 2009-08-31 Raised $4.6M (real) Modeled valuation $166M (est)Series A2009Series B · 2010-05-28 Raised $601K (real) Modeled valuation $24M (est)Series B2010Series B · 2011-06-30 Raised $4.9M (real) Modeled valuation $195M (est)Series B2011Series C · 2011-12-15 Raised $40M (real) Modeled valuation $1.6B (est)Series C2011Series B · 2011-12-15 Raised $35M (real) Modeled valuation $1.4B (est)Series B2011Series C · 2015-11-24 Raised $2.4M (real) Modeled valuation $98M (est)Series C2015Series C · 2015-11-24 Raised $1.9M (real) Modeled valuation $79M (est)Series C2015+$3.4M+$17M+$4.6M+$601K+$4.9M+$40M+$35M+$2.4M+$1.9MCumulative $113M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.1M · 2008
Seed extension$3.4M · 2009
Series B$16.9M · 2009no Series A on file
Bridge · Series B-stage$4.6M · 2009smaller follow-on
Series B extension$601K · 2010
Series B extension$4.9M · 2011
Series C$40.3M · 2011
Bridge · Series C-stage$35.1M · 2011smaller follow-on
Series C extension$2.4M · 2015
Series C extension$1.9M · 2015

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.

Modeled valuation trajectory
$98.2M
Base estimate est.
$7.4M
Conservative case
$258.6M
Upside case
$16.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $139.3M · 2008-12-222008Seed · modeled $149.2M · 2009-08-31Series B · modeled $670.4M · 2009-08-31Series A · modeled $165.7M · 2009-08-31Series B · modeled $23.8M · 2010-05-28Series B · modeled $195.3M · 2011-06-30Series C · modeled $1.6B · 2011-12-15Series B · modeled $1.4B · 2011-12-15Series C · modeled $98.2M · 2015-11-24Series C · modeled $79.0M · 2015-11-242015
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
6.0 yr
Elapsed time used
10.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$16.4M/yr
Capital velocity
17.5 yr
On record since
2008
First round
10
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 16× above median
This company$113.2M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.0× of median
This company$1.9M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 1.5× above median
This company$98.2M
Sector median$64.2M

Raised more than 91% of sector peers (real $). Modeled value above 58% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #40 of 41.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Antigenics LLC/DE · Series C Raised $100.0M · modeled $4.1B (est)Naurex Inc. · Series C Raised $156.0M · modeled $3.3B (est)Fluidigm Corp · Series C Raised $111.0M · modeled $3.1B (est)Tengion Inc · Series C Raised $121.7M · modeled $3.0B (est)Spark Therapeutics, Inc. · Series C Raised $72.8M · modeled $3.0B (est)X-Co Holdings, LP · Series C Raised $71.0M · modeled $2.9B (est)REGENXBIO Inc. · Series C Raised $105.9M · modeled $2.9B (est)C4 Therapeutics, Inc. · Series C Raised $70.3M · modeled $2.9B (est)Intra-Cellular Therapies, Inc. · Series C Raised $70.3M · modeled $2.9B (est)Intellia Therapeutics, Inc. · Series C Raised $70.0M · modeled $2.9B (est)Chiasma Inc · Series C Raised $150.5M · modeled $2.9B (est)AveXis, Inc. · Series C Raised $65.0M · modeled $2.7B (est)Uptake Medical Corp (this company) Raised $113.2M · modeled $98.2M (est)Uptake Medical Corp
CompanyStageRaised · realValue · estvs peer med.
Antigenics LLC/DESeries C$100.0M$4.1B1.81×
Naurex Inc.Series C$156.0M$3.3B1.45×
Fluidigm CorpSeries C$111.0M$3.1B1.39×
Tengion IncSeries C$121.7M$3.0B1.34×
Spark Therapeutics, Inc.Series C$72.8M$3.0B1.32×
X-Co Holdings, LPSeries C$71.0M$2.9B1.29×
REGENXBIO Inc.Series C$105.9M$2.9B1.28×
C4 Therapeutics, Inc.Series C$70.3M$2.9B1.27×
Intra-Cellular Therapies, Inc.Series C$70.3M$2.9B1.27×
Intellia Therapeutics, Inc.Series C$70.0M$2.9B1.27×
Chiasma IncSeries C$150.5M$2.9B1.26×
AveXis, Inc.Series C$65.0M$2.7B1.18×
Uptake Medical Corp this companySeries C$113.2M$98.2M0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.1M2008-12-22$15.7M$139.3M90%
Seed$3.4M2009-08-31$16.8M$149.2M90%
Series B$16.9M2009-08-31$93.8M$670.4M90%
Series A$4.6M2009-08-31$20.8M$165.7M90%
Series B$601K2010-05-28$3.3M$23.8M90%
Series B$4.9M2011-06-30$27.3M$195.3M90%
Series C$40.3M2011-12-15$268.4M$1.6B90%
Series B$35.1M2011-12-15$195.0M$1.4B90%
Series C$2.4M2015-11-24$16.0M$98.2M90%
Series C$1.9M2015-11-24$12.9M$79.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.1M2008-12-22
    • First recorded raise — entered as Seed.
  2. Seed$3.4M2009-08-31
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  3. Series B$16.9M2009-08-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.0× larger than the prior — scaling up.
  4. Series A$4.6M2009-08-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.7× smaller than the prior — bridge or down round.
  5. Series B$601K2010-05-28
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 7.6× smaller than the prior — bridge or down round.
  6. Series B$4.9M2011-06-30
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 8.2× larger than the prior — scaling up.
  7. Series C$40.3M2011-12-15
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 8.2× larger than the prior — scaling up.
  8. Series B$35.1M2011-12-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  9. Series C$2.4M2015-11-24
    • Raised again after 47 mo — slower than the ~14 mo sector norm.
    • Round 14.6× smaller than the prior — bridge or down round.
  10. Series C$1.9M2015-11-24
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
Intelligence
2016 ~Q3
Modeled next raise · ~9mo cadence
$1.9M
Modeled next size est.range $1.9M$3.1M
0.8×
Last step-up
$16.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
John Brooks7 other2008-12
Eric Kim6 other2011-06
Scott Huennekens6 other2011-06
Andrew Schiff4 other2011-12
Carl Simpson3 other2008-12
Michael Hoey3 other2008-12
J.C. MacRae2 other2011-06
Geoff Brooke1 other2008-12
R. King Nelson1 other2008-12
Robert Barry1 other2011-06
Carl King Simpson2015-11
Carl King Simson2015-11
David King Singer2015-11
Eric L. Kim2009-08
Geoff King Brooke2015-11
Krista King Mann2015-11
Krista L. Mann2009-08
Krista Mann2008-12
Robert King Kuhling2015-11
Robert Kuhling, Jr.2008-12
Robert L. Barry2008-12
Robert L. Kuhling, Jr.2009-08
Sami King Sindi2015-11
Sami Sindi2011-12
Registry & provenance

Uptake Medical Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1316760
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Elucid Bioimaging Inc.BiotechnologySeries C$115.8M$200.2Mnetwork1 shared operator · same sector · same stage
Ekso Bionics Holdings, Inc.BiotechnologySeries C$112.0M$113.4Msame sector · same stage
OncoNano Medicine, Inc.BiotechnologySeries C$115.0M$84.2Msame sector · same stage
Cardiaq Valve Technologies IncBiotechnologySeries B$77.2M$1.5Bnetwork1 shared operator · same sector
NextCure, Inc.BiotechnologySeries C$129.9M$113.9Msame sector · same stage
Ra Medical Systems, Inc.BiotechnologySeries C$98.0M$116.1Msame sector · same stage
Iterum Therapeutics LtdBiotechnologySeries C$131.4M$115.9Msame sector · same stage
Axcella Health Inc.BiotechnologySeries C$92.8M$105.5Msame sector · same stage
Frequently asked
How much funding has Uptake Medical Corp raised?
Uptake Medical Corp has raised approximately $113.2M in disclosed capital across 10 recorded financing rounds, aggregated from public filings.
What is Uptake Medical Corp's estimated valuation?
Provath's modeled valuation for Uptake Medical Corp is approximately $98.2M (modeled range $7.4M–$258.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Uptake Medical Corp at?
Uptake Medical Corp's latest modeled financing stage is Series C. Its most recent recorded round closed around Tue Nov 24.
What does Uptake Medical Corp do and where is it based?
Uptake Medical Corp operates in the Biotechnology sector, based in Tustin.
Explore related

See where Uptake Medical Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Uptake Medical Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.